| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | July 18, 2024 5:00 P.M. |
| Form: | S-3 | ||||||
| |||||||
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/7/2024 | $7.00 | Buy | H.C. Wainwright |
| 4/24/2024 | $8.00 | Buy | Craig Hallum |
| 6/22/2023 | $7.00 | Perform → Outperform | Oppenheimer |
| 6/30/2021 | $38.00 → $32.00 | Buy | Roth Capital |
Conference Call and Webcast Thursday November 14 at 8:00 AM Eastern Time / 7:00 AM Central Time Implemented Updates to AIS Program Intended to Enhance Probability of Trial Success and Expedite Study Completion, with Potential for a Reduced Study Size Preeclampsia Phase 2 Trial Received Regulatory Approval and First Patient Dosed Cash Runway Into Q3 2026 DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today provided a business update and financial results for the quarter ended September 30, 2024. Management will host a conference call Thursday, November 14, 2024, at 8:00 AM
DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced that the first patient has been dosed in DiaMedica's investigator-sponsored Phase 2 trial of DM199 for the treatment of preeclampsia (PE). DiaMedica anticipates top line data for Part 1A in the first half of 2025 which is expected to demonstrate initial proof-of-concept including whether DM199 is safe and lowers blood pressure. Additionally, for patients with early onset PE, DiaMedica will be looking for improvements in uterine artery dilation, indicating that DM199 therapy is potentially disease modifying in these patient
DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today that the Company's management will attend the 15th Annual Craig-Hallum Alpha Select Conference on Tuesday, November 19, 2024 in New York City, New York. Management will be available for one-on-one meetings throughout the day. Investors and attendees that would like to schedule a meeting with DiaMedica's management can contact their Craig-Hallum representative to arrange a meeting. About DiaMedica Therapeutics Inc. DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the liv
4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)
4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)
4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)
4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)
4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)
4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)
H.C. Wainwright initiated coverage of DiaMedica Therapeutics with a rating of Buy and set a new price target of $7.00
Craig Hallum resumed coverage of DiaMedica Therapeutics with a rating of Buy and set a new price target of $8.00
Oppenheimer upgraded DiaMedica Therapeutics from Perform to Outperform and set a new price target of $7.00
Company to Host Preeclampsia Key Opinion Leader Event July 29, 2024 at 10 AM Eastern / 9 AM CentralWhite Paper: The Potential of DM199 to Treat PreeclampsiaDiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic disease, today announced that it will host a virtual key opinion leader (KOL) event on Monday, July 29, 2024, at 10:00 AM ET to provide further insight into the expansion of its clinical development program for DM199 (rinvecalinase alfa) into preeclampsia, a significant, unmet medical need with no FDA-approved therapeutics.
- SEC Filing
Conference Call and Webcast Thursday November 14 at 8:00 AM Eastern Time / 7:00 AM Central Time Implemented Updates to AIS Program Intended to Enhance Probability of Trial Success and Expedite Study Completion, with Potential for a Reduced Study Size Preeclampsia Phase 2 Trial Received Regulatory Approval and First Patient Dosed Cash Runway Into Q3 2026 DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today provided a business update and financial results for the quarter ended September 30, 2024. Management will host a conference call Thursday, November 14, 2024, at 8:00 AM
DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today that its third quarter 2024 financial results will be released after market close on Wednesday, November 13th. DiaMedica will host a live conference call on Thursday, November 14th at 7:00 AM Central Time to provide a business update and discuss financial results. Conference Call details: Date: Thursday, November 14, 2024 Time: 7:00 AM CT / 8:00 AM ET Web access: https://app.webinar.net/8B2w698qkyb Dial In: (646) 357-8785 Conference ID: 28056 Interested parties may access the conf
Conference Call and Webcast August 8 at 8:00 AM Eastern Time / 7:00 AM Central Time Acute Ischemic Stroke (AIS) Phase 2/3 ReMEDy2 Trial Interim Enrollment (n=144) Targeted for Q1 2025 Preeclampsia Phase 2 Investigator-sponsored Trial Beginning in Q4 2024 with Proof-of-Concept Results Targeted for First Half 2025 Completed $12 Million Private Placement, Extending Cash Runway Into Q3 2026 DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today provided a business update and financial results for the quarter ended June 30, 2024. Management will host a conference call Thursday, A
10-Q - DiaMedica Therapeutics Inc. (0001401040) (Filer)
8-K - DiaMedica Therapeutics Inc. (0001401040) (Filer)
8-K - DiaMedica Therapeutics Inc. (0001401040) (Filer)
SC 13G - DiaMedica Therapeutics Inc. (0001401040) (Subject)
SC 13G/A - DiaMedica Therapeutics Inc. (0001401040) (Subject)
SC 13G/A - DiaMedica Therapeutics Inc. (0001401040) (Subject)
Executive with Strong Track Record in Advancing Pipelines Through Clinical Development DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, announced today the appointment of Lorianne Masuoka, M.D. as Chief Medical Officer. Dr. Masuoka is a board-certified neurologist with more than 25 years of experience and a successful track record of managing clinical programs from early stage to drug approvals and strategic alliances. "We are delighted to have Lorianne join our executive leadership team," said Rick Pauls, DiaMedica's President and Chief Executive Officer. "Sh
Dr. Shah Has Spent Over Two Decades Leading Biological Development Teams at Biotechnology Companies and Has Deep Expertise in Protein Development and Manufacturing DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, announced today the appointment of Ambarish Shah, Ph.D. as Chief Technology Officer. Dr. Shah will lead the development of DiaMedica's manufacturing operations for the late-stage drug candidate DM199. Since May 2023, Dr. Shah has been advising DiaMedica as it worked through the final resolution of the clinical hold on the investigational new drug applic
Recently Retired Medtronic Chief Medical Officer and Chief Scientific Officer with Deep Expertise in Stroke Treatment DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on acute ischemic stroke and other vascular diseases, today announced the appointment of Dr. Richard Kuntz to its Board of Directors effective May 30, 2023. Dr. Richard Kuntz recently retired from Medtronic plc (NYSE:MDT) where he was the Chief Medical Officer & Scientific Officer and a member of the Executive Committee. Prior to that, he served as Senior Vice President and President, Neuromodulation of Medtronic from October 2005 to August 2009. Before joining Medtronic, he was